Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)

Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy

(2018) Derek B. Oien et al.   Frontiers in Pharmacology

Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions

(2018) Yuka Kato et al.   CANCER SCIENCE

AXL Mediates Esophageal Adenocarcinoma Cell Invasion through Regulation of Extracellular Acidification and Lysosome Trafficking

(2018) Selma Maacha et al.   NEOPLASIA

The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells

(2017) Terumichi Shintani et al.   UROLOGY

Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin

(2017) Yong Hu et al.   OncoTargets and Therapy

AXL is a marker for epithelial‑mesenchymal transition in esophageal squamous cell carcinoma

(2017) Guoan Zhang et al.   Oncology Letters

Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models

(2017) Zhiqiang Guo et al.   Oncotarget

Targeting the Human Epidermal Growth Factor Receptor 2 in Esophageal Cancer

(2017) Khaldoun Almhanna et al.   Cancer Control

In Vivo Visualization and Characterization of Epithelial–Mesenchymal Transition in Breast Tumors

(2016) Zhen Zhao et al.   CANCER RESEARCH

Regulation of theMEToncogene: molecular mechanisms

(2016) Jack Zhang et al.   CARCINOGENESIS

Cabozantinib: A Review in Advanced Renal Cell Carcinoma

(2016) Zaina T. Al-Salama et al.   DRUGS

Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors

(2016) Estelle Daudigeos-Dubus et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

(2016) Alexander Drilon et al.   LANCET ONCOLOGY

CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation

(2016) Dan-Dan Wang et al.   MOLECULAR CANCER THERAPEUTICS

The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma

(2016) Min-Shu Hsieh et al.   Oncotarget

C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome

(2016) Ya-Ping Xu et al.   Journal of Cancer

Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma

(2015) Yingying Xu et al.   BMC CANCER

c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target

(2015) Yohei Ozawa et al.   BMC CANCER

AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

(2015) Moshe Elkabets et al.   CANCER CELL

Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models

(2015) M. Sameni et al.   CLINICAL CANCER RESEARCH

Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity

(2015) X. Wang et al.   CLINICAL CANCER RESEARCH

The effect of ephrin-A1 on resistance to Photofrin-mediated photodynamic therapy in esophageal squamous cell carcinoma cells

(2015) Pei-Wen Yang et al.   LASERS IN MEDICAL SCIENCE

Cabozantinib in Thyroid Cancer

(2015) Poupak Fallahi et al.   Recent Patents on Anti-Cancer Drug Discovery

MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas

(2015) Katja Schmitz et al.   PLoS One

Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET

(2014) Q. Xiang et al.   CLINICAL CANCER RESEARCH

Targeted therapies in metastatic esophageal cancer: Advances over the past decade

(2014) Amr Mohamed et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

(2014) Susan J Dutton et al.   LANCET ONCOLOGY

Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein

(2014) Qing-feng Xiang et al.   LIVER INTERNATIONAL

Esophageal Carcinoma

(2014) Anil K. Rustgi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions

(2013) Jinlu Dai et al.   CLINICAL CANCER RESEARCH

A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1

(2013) Jun Sung Lee et al.   NEURO-ONCOLOGY

The effects of Photofrin-mediated photodynamic therapy on the modulation of EGFR in esophageal squamous cell carcinoma cells

(2012) Pei-Wen Yang et al.   LASERS IN MEDICAL SCIENCE

Current Developments in the Management of Locally Advanced Esophageal Cancer

(2012) Michael J. McNamara et al.   Current Oncology Reports

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus

(2010) David H. Ilson et al.   CANCER

R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer

(2010) S. J. Holland et al.   CANCER RESEARCH

BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor-Stimulated Prostate Cancer Metastatic Phenotype In vitro

(2010) Y. Dai et al.   MOLECULAR CANCER THERAPEUTICS

Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced Survival

(2009) James M. Donahue et al.   ANNALS OF THORACIC SURGERY

Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer

(2009) William H. Allum et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery ofN-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily

(2009) Gretchen M. Schroeder et al.   JOURNAL OF MEDICINAL CHEMISTRY

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

(2009) C. Gjerdrum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cadherin switching

(2008) M. J. Wheelock et al.   JOURNAL OF CELL SCIENCE